Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Fineline Cube Apr 13, 2026
Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Fineline Cube Apr 13, 2026
Company Drug

Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment

Fineline Cube Mar 31, 2025

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in...

Company Drug

Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly

Fineline Cube Mar 31, 2025

Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...

Company Deals

Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment

Fineline Cube Mar 31, 2025

Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based...

Company Deals Drug

Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone

Fineline Cube Mar 31, 2025

Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration...

Company

EClinCloud Secures New Funding to Accelerate AI Innovation in Clinical Research

Fineline Cube Mar 30, 2025

EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions,...

Medical Device Policy / Regulatory

China Tightens Medical Device Quality Oversight: 2025 Inspection Plan Unveiled

Fineline Cube Mar 29, 2025

China’s National Medical Products Administration (NMPA) has released its 2025 medical device inspection plan, outlining...

Policy / Regulatory

Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications

Fineline Cube Mar 29, 2025

Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list...

Policy / Regulatory

Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics

Fineline Cube Mar 29, 2025

The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized...

Medical Device Policy / Regulatory

China Unveils 2025 Medical Device Inspection Strategy to Tighten Quality Control

Fineline Cube Mar 29, 2025

China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24...

Company Deals Drug

Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma

Fineline Cube Mar 29, 2025

Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...

Company Drug

Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention

Fineline Cube Mar 29, 2025

Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its...

Policy / Regulatory

Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement

Fineline Cube Mar 29, 2025

Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...

Company Medical Device

Abbott Laboratories’ Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment

Fineline Cube Mar 28, 2025

US-based Abbott Laboratories (NYSE: ABT) has announced the receipt of the CE mark in the...

Company Deals

Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy

Fineline Cube Mar 28, 2025

US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake...

Company Drug

Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment

Fineline Cube Mar 28, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour...

Company

CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline

Fineline Cube Mar 28, 2025

China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues...

Company Deals Drug

TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies

Fineline Cube Mar 28, 2025

Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...

Company Drug

NMPA Approves Qingfeng’s Suraxavir Marboxil for Influenza A and B Treatment

Fineline Cube Mar 28, 2025

China’s National Medical Products Administration (NMPA) has approved suraxavir marboxil, a Category 1 drug developed...

Company

Medtronic Launches Digital Innovation Base in Beijing’s BioPark

Fineline Cube Mar 28, 2025

US-Irish firm Medtronic (NYSE: MDT) has inaugurated its digital medical innovation base at the BioPark...

Company Drug

Huadong Medicine Gains NMPA Approval for HDM3019 Rheumatoid Arthritis Trial

Fineline Cube Mar 28, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced receiving approval from the National Medical Products...

Posts pagination

1 … 170 171 172 … 649

Recent updates

  • CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine
  • Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value
  • Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines
  • Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle
  • Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.